Hyperion DeFi, Inc. (HYPD) Fair Value 2026

HYPD · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.1 /10

32 fundamental signals · 12 models active

Value Trap Risk

LOW (32/100)

Quick Summary — As of 2026-07-15, Hyperion DeFi, Inc. (HYPD) trades at $3.02, approximately 218% above CirclFi’s Bayesian DCF fair value of $0.95. QOC: 5.1/10. Value Trap Risk: 32/100 (LOW). 12/13 models active.

Key Facts

Ticker
HYPD
Price
$3.02
Quality Score
5.1/10
Value Trap Risk
32/100
Models Active
12/13
Last Updated
Strength: Earnings Power Value suggests +124.0% upside with 24% confidence
Risk: Majority of models suggest overvaluation

Is Hyperion DeFi, Inc. (HYPD) Undervalued or Overvalued in 2026?

According to CirclFi’s 12-model valuation engine, Hyperion DeFi, Inc. (HYPD) appears overvalued as of : the median of 12 independent fair value estimates is $1.58, 47.6% below the current price of $3.02. Estimates range from $0.04 to $6.85. HYPD scores 5.1/10 on fundamental quality and 32/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Hyperion DeFi, Inc. Stock in 2026? →

Valuation Matrix

12 Intrinsic Value Models vs. Current Price ($3.02)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
$0.95 -68.6%
Earnings Power Value
Medium Conviction
$6.76 +124.0%
CUCE Ensemble
Low Conviction
$2.21 -26.7%
First Chicago
Medium Conviction
$0.83 -72.4%

Unlock the Full Matrix

Access 8 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 12 Models →

Cancel anytime · No contracts · Instant access

What Is Hyperion DeFi, Inc. (HYPD) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Hyperion DeFi, Inc. at its current price of $3.02. The composite intrinsic value is estimated at $2.60 (-13.9% average return), with 7 models flagging overvaluation risk. The most optimistic model, FTNN, places fair value at $6.85 (+126.7%), while Markov DDM — the most conservative — estimates $0.04 (-98.7%). This +225.5% gap reflects genuine analytical uncertainty about Hyperion DeFi, Inc.'s intrinsic worth.

What Do the Models Say About HYPD?

12 of 13 models are currently active for HYPD. Of these, 5 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates HYPD's intrinsic value at $0.95, implying -68.6% downside from the current price. See which stocks rank higher →

How Does HYPD Rank in Pharmaceutical Preparations?

Among 431 Pharmaceutical Preparations stocks, HYPD ranks #188 by Quality of Company score. CirclFi's QOC score of 5.1/10 evaluates 32 fundamental signals. A score of 5.1 reflects mixed fundamentals.

See all Most Undervalued Pharmaceutical Preparations Stocks →

Within the Pharmaceutical Preparations space, Hyperion DeFi, Inc. competes in an environment where biosimilar competition timeline often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is HYPD a Value Trap?

CirclFi's Value Trap algorithm assigns HYPD a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

12 of 13 models are active for Hyperion DeFi, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Hyperion DeFi, Inc. is rated at 5.1/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

The gap between the most bullish and bearish model spans +225.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every HYPD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across HYPD's 12 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Hyperion DeFi, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Preparations Stocks Should You Also Analyze?

8 related Pharmaceutical Preparations stocks with 13-model coverage

Read investment analysis: AZN · CPRX · HRMY · NVO · SIGA

See all Pharmaceutical Preparations stocks ranked →

Frequently Asked Questions About Hyperion DeFi, Inc.

What is Hyperion DeFi, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Hyperion DeFi, Inc. (HYPD) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.95. The Quality of Company score is 5.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is HYPD overvalued or undervalued right now?

At $3.02, 5 of 12 active models suggest HYPD may be undervalued, while 7 indicate potential overvaluation. The median of all 12 fair value estimates is $1.58, 47.6% below the current price of $3.02 — a consensus view that HYPD is overvalued. The assessment depends on which methodology best fits Hyperion DeFi, Inc.'s business model in Pharmaceutical Preparations.

What does a Quality of Company score of 5.1 mean for HYPD?

Hyperion DeFi, Inc.'s QOC of 5.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on HYPD?

CirclFi analyzes HYPD with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 12 of 13 are active for this stock. Read the full methodology →

Is HYPD a value trap in 2026?

Hyperion DeFi, Inc.'s Value Trap score is 32/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 12-model valuation engine, Hyperion DeFi, Inc. (HYPD) has a median fair value of $1.58 — 47.6% below the current price of $3.02 — as of 2026-07-15.” Source: circlfi.com/stock/HYPD/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 12 mathematical frameworks give you clarity on HYPD.

Unlock All 12 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access